FDA快速通道指定-话题@MedSci

#FDA快速通道指定#

12篇内容 | 770人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1404374, encodeId=89d914043e4b7, content=<a href='/topic/show?id=b80be308fc' target=_blank style='color:#2F92EE;'>#FDA快速通道指定#</a>, objectTitle=BTK抑制剂Rilzabrutinib治疗免疫性血小板减少症：被授予FDA快速通道指定, objectType=article, longId=203551, objectId=920d203551ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=920d203551ad, replyNumber=0, likeNumber=55, createdTime=2020-11-21, rootId=0, userName=changfy, userId=65072466385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=920d203551ad, moduleTitle=BTK抑制剂Rilzabrutinib治疗免疫性血小板减少症：被授予FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=920d203551ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404373, encodeId=02e214043e379, content=<a href='/topic/show?id=b80be308fc' target=_blank style='color:#2F92EE;'>#FDA快速通道指定#</a>, objectTitle=CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定, objectType=article, longId=202384, objectId=f40b202384ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f40b202384ce, replyNumber=0, likeNumber=34, createdTime=2020-10-24, rootId=0, userName=changfy, userId=65072466385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f40b202384ce, moduleTitle=CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f40b202384ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404372, encodeId=bf1814043e2dc, content=<a href='/topic/show?id=b80be308fc' target=_blank style='color:#2F92EE;'>#FDA快速通道指定#</a>, objectTitle=非酒精性脂肪性肝炎新药HM15211，获得FDA快速通道指定, objectType=article, longId=197673, objectId=890919e6737a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=890919e6737a, replyNumber=0, likeNumber=36, createdTime=2020-07-19, rootId=0, userName=changfy, userId=65072466385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=890919e6737a, moduleTitle=非酒精性脂肪性肝炎新药HM15211，获得FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=890919e6737a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404371, encodeId=294314043e1e5, content=<a href='/topic/show?id=b80be308fc' target=_blank style='color:#2F92EE;'>#FDA快速通道指定#</a>, objectTitle=获得1亿美元融资以及FDA快速通道指定后，荣昌生物再次获得FDA批准——启动抗HER2的ADC药物治疗尿路上皮癌的II期临床试验, objectType=article, longId=193386, objectId=63df19338615, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63df19338615, replyNumber=0, likeNumber=36, createdTime=2020-05-04, rootId=0, userName=changfy, userId=65072466385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63df19338615, moduleTitle=获得1亿美元融资以及FDA快速通道指定后，荣昌生物再次获得FDA批准——启动抗HER2的ADC药物治疗尿路上皮癌的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63df19338615)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404370, encodeId=6a3614043e0b2, content=<a href='/topic/show?id=b80be308fc' target=_blank style='color:#2F92EE;'>#FDA快速通道指定#</a>, objectTitle=获得1亿美元融资后，荣昌生物的融合蛋白TACI-Fc治疗红斑狼疮获得FDA快速通道指定, objectType=article, longId=192487, objectId=54e819248eed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54e819248eed, replyNumber=0, likeNumber=51, createdTime=2020-04-20, rootId=0, userName=changfy, userId=65072466385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54e819248eed, moduleTitle=获得1亿美元融资后，荣昌生物的融合蛋白TACI-Fc治疗红斑狼疮获得FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54e819248eed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404369, encodeId=cd061404369c7, content=<a href='/topic/show?id=b80be308fc' target=_blank style='color:#2F92EE;'>#FDA快速通道指定#</a>, objectTitle=Alnylam的RNAi疗法Vutrisiran获得FDA快速通道指定，治疗hATTR淀粉样变性, objectType=article, longId=192376, objectId=8eeb1923e6a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8eeb1923e6a6, replyNumber=0, likeNumber=32, createdTime=2020-04-17, rootId=0, userName=changfy, userId=65072466385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8eeb1923e6a6, moduleTitle=Alnylam的RNAi疗法Vutrisiran获得FDA快速通道指定，治疗hATTR淀粉样变性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8eeb1923e6a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404368, encodeId=c081140436844, content=<a href='/topic/show?id=b80be308fc' target=_blank style='color:#2F92EE;'>#FDA快速通道指定#</a>, objectTitle=Daré Bioscience的克林霉素水凝胶DARE-BV1获得FDA快速通道指定，用于治疗细菌性阴道病, objectType=article, longId=189906, objectId=d87818990695, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d87818990695, replyNumber=0, likeNumber=42, createdTime=2020-03-14, rootId=0, userName=changfy, userId=65072466385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d87818990695, moduleTitle=Daré Bioscience的克林霉素水凝胶DARE-BV1获得FDA快速通道指定，用于治疗细菌性阴道病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d87818990695)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404367, encodeId=2331140436e09, content=<a href='/topic/show?id=b80be308fc' target=_blank style='color:#2F92EE;'>#FDA快速通道指定#</a>, objectTitle=Moderna的mRNA纳米药物（mRNA-3927）治疗丙酸血症，获得FDA快速通道指定, objectType=article, longId=181809, objectId=4c8c18180917, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c8c18180917, replyNumber=0, likeNumber=55, createdTime=2019-10-25, rootId=0, userName=changfy, userId=65072466385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c8c18180917, moduleTitle=Moderna的mRNA纳米药物（mRNA-3927）治疗丙酸血症，获得FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c8c18180917)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404366, encodeId=50ba140436632, content=<a href='/topic/show?id=b80be308fc' target=_blank style='color:#2F92EE;'>#FDA快速通道指定#</a>, objectTitle=DiscGenics用于治疗椎间盘退变的细胞疗法，获得FDA快速通道指定, objectType=article, longId=178239, objectId=15071e82392b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15071e82392b, replyNumber=0, likeNumber=37, createdTime=2019-08-29, rootId=0, userName=changfy, userId=65072466385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15071e82392b, moduleTitle=DiscGenics用于治疗椎间盘退变的细胞疗法，获得FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15071e82392b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404365, encodeId=8d35140436568, content=<a href='/topic/show?id=b80be308fc' target=_blank style='color:#2F92EE;'>#FDA快速通道指定#</a>, objectTitle=Akari的补体抑制剂Nomacopan治疗小儿造血干细胞移植相关血栓性微血管病，获得FDA快速通道指定, objectType=article, longId=177725, objectId=7f3b1e772586, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f3b1e772586, replyNumber=0, likeNumber=36, createdTime=2019-08-17, rootId=0, userName=changfy, userId=65072466385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f3b1e772586, moduleTitle=Akari的补体抑制剂Nomacopan治疗小儿造血干细胞移植相关血栓性微血管病，获得FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f3b1e772586)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404364, encodeId=5fb814043642e, content=<a href='/topic/show?id=b80be308fc' target=_blank style='color:#2F92EE;'>#FDA快速通道指定#</a>, objectTitle=Themis Bioscience公司的基孔肯雅热预防疫苗获得了FDA快速通道指定, objectType=article, longId=161115, objectId=4e211611157a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e211611157a, replyNumber=0, likeNumber=32, createdTime=2019-02-27, rootId=0, userName=changfy, userId=65072466385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e211611157a, moduleTitle=Themis Bioscience公司的基孔肯雅热预防疫苗获得了FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e211611157a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1404363, encodeId=b0c51404363b1, content=<a href='/topic/show?id=b80be308fc' target=_blank style='color:#2F92EE;'>#FDA快速通道指定#</a>, objectTitle=GRANITE-001获得FDA快速通道指定用于治疗结直肠癌, objectType=article, longId=156452, objectId=419115645287, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=419115645287, replyNumber=0, likeNumber=42, createdTime=2018-12-24, rootId=0, userName=changfy, userId=65072466385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=419115645287, moduleTitle=GRANITE-001获得FDA快速通道指定用于治疗结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=419115645287)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FDA快速通道指定

2020-05-29

changfy (审核中...)

前往app查看评论内容

#FDA快速通道指定#

BTK抑制剂Rilzabrutinib治疗免疫性血小板减少症：被授予FDA快速通道指定

2020-11-21

changfy (审核中...)

前往app查看评论内容

#FDA快速通道指定#

CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定

2020-10-24

changfy (审核中...)

前往app查看评论内容

#FDA快速通道指定#

非酒精性脂肪性肝炎新药HM15211，获得FDA快速通道指定

2020-07-19

changfy (审核中...)

前往app查看评论内容

#FDA快速通道指定#

获得1亿美元融资以及FDA快速通道指定后，荣昌生物再次获得FDA批准——启动抗HER2的ADC药物治疗尿路上皮癌的II期临床试验

2020-05-04

changfy (审核中...)

前往app查看评论内容

#FDA快速通道指定#

获得1亿美元融资后，荣昌生物的融合蛋白TACI-Fc治疗红斑狼疮获得FDA快速通道指定

2020-04-20

changfy (审核中...)

前往app查看评论内容

#FDA快速通道指定#

Alnylam的RNAi疗法Vutrisiran获得FDA快速通道指定，治疗hATTR淀粉样变性

2020-04-17

changfy (审核中...)

前往app查看评论内容

#FDA快速通道指定#

Daré Bioscience的克林霉素水凝胶DARE-BV1获得FDA快速通道指定，用于治疗细菌性阴道病

2020-03-14

changfy (审核中...)

前往app查看评论内容

#FDA快速通道指定#

Moderna的mRNA纳米药物（mRNA-3927）治疗丙酸血症，获得FDA快速通道指定

2019-10-25

changfy (审核中...)

前往app查看评论内容

#FDA快速通道指定#

DiscGenics用于治疗椎间盘退变的细胞疗法，获得FDA快速通道指定

2019-08-29

changfy (审核中...)

前往app查看评论内容

#FDA快速通道指定#

Akari的补体抑制剂Nomacopan治疗小儿造血干细胞移植相关血栓性微血管病，获得FDA快速通道指定

2019-08-17

changfy (审核中...)

前往app查看评论内容

#FDA快速通道指定#

Themis Bioscience公司的基孔肯雅热预防疫苗获得了FDA快速通道指定

2019-02-27

changfy (审核中...)

前往app查看评论内容

#FDA快速通道指定#

GRANITE-001获得FDA快速通道指定用于治疗结直肠癌

2018-12-24

科室
- - 订阅+
  - 更多科室
工具
服务